Thyroid Eye Symptoms: Causes, Treatments, and What Women Need to Know

What Are Thyroid Eye Symptoms, Exactly?

Thyroid eye symptoms are a cluster of orbital and ocular changes driven by autoimmune inflammation targeting the tissues behind and around your eyes. The medical term is thyroid eye disease (TED), sometimes called Graves' ophthalmopathy or thyroid-associated orbitopathy.

The inflammation causes fat and muscle tissue in the eye socket to swell, pushing the eyeball forward. That forward displacement, called proptosis or exophthalmos, is the signature sign most people picture, but TED presents in many other ways before the eyes visibly bulge.

The Full Symptom Spectrum

Common early symptoms include:

• Gritty, dry, or irritated eyes that feel worse in the morning
• Puffy upper or lower eyelids, sometimes mistaken for allergies or lack of sleep
• Lid retraction, where the upper lid sits higher than normal, giving a startled appearance
• Sensitivity to light (photophobia)
• Excessive tearing despite underlying dryness

As the condition progresses, symptoms may include:

• Proptosis (eyes appearing to protrude)
• Diplopia, meaning double vision, caused by thickening of the extraocular muscles
• Reduced color vision or visual acuity, signaling optic nerve compression
• Eye pain with eye movement

Optic nerve compression affects roughly 5 to 10 percent of people with TED and represents the most sight-threatening complication.

Why Women Are Disproportionately Affected

Graves' disease affects women about seven to ten times more often than men, and TED follows that same female predominance, with incidence roughly five times higher in women. The reasons are rooted in sex-specific immune regulation. Estrogen shifts immune responses toward Th2-predominant autoimmunity, and X-linked immune genes contribute to a higher baseline autoantibody burden in women. Thyroid-stimulating hormone receptor (TSHR) autoantibodies, the key drivers of TED, correlate directly with orbital inflammation severity.

What Causes Thyroid Eye Symptoms?

TED is caused by autoimmune activation of the insulin-like growth factor 1 receptor (IGF-1R) and TSHR on orbital fibroblasts, triggering glycosaminoglycan accumulation, tissue expansion, and fat remodeling. The TSHR-IGF-1R signaling complex is now considered the central molecular target in TED.

Graves' Disease: The Primary Driver

Graves' disease accounts for approximately 90 percent of TED cases. Thyroid eye symptoms can appear before, during, or after a Graves' diagnosis, and the severity of eye disease does not reliably track with how controlled your thyroid hormone levels are. Your eyes can worsen even after your TSH normalizes.

Hashimoto's Thyroiditis and Euthyroid TED

About 5 to 6 percent of TED cases occur in people with Hashimoto's thyroiditis or entirely normal thyroid function, a presentation called euthyroid TED. This is frequently missed because clinicians assume normal thyroid labs rule out TED. If your eyes look or feel wrong and your thyroid labs are normal, TSHR antibody (TRAb) testing is still warranted.

Radioiodine Therapy as a Risk Factor

Radioiodine-131 (RAI) used to treat Graves' hyperthyroidism carries a documented risk of triggering or worsening TED. A randomized controlled trial by Tallstedt et al. Published in the NEJM found that RAI caused new or worsened ophthalmopathy in 23 percent of Graves' patients versus 3 percent treated with antithyroid drugs. Prophylactic oral prednisone given alongside RAI reduces, but does not eliminate, this risk. If you are considering RAI and you already have any degree of eye involvement, discuss orbital protection strategies with your clinician before proceeding.

Smoking

Smoking is the most modifiable risk factor for TED. Smokers with Graves' disease are approximately twice as likely to develop TED, and their disease runs a more severe course. Even secondhand smoke exposure is associated with worse outcomes. Quitting smoking before or during TED treatment meaningfully improves response to therapy.

Drugs That Cause or Worsen Thyroid Eye Symptoms

Several medications can precipitate or aggravate TED, and understanding this matters especially if you are managing other conditions common in women.

Radioiodine (Iodine-131)

As covered above, RAI can trigger orbital inflammation in Graves' patients. The risk is highest in those who already have mild eye involvement, are current smokers, or have high pretreatment TRAb levels. Antithyroid drugs (methimazole or propylthiouracil) and thyroid surgery carry a lower TED risk than RAI and may be preferable if you have active eye symptoms.

Amiodarone

Amiodarone, an antiarrhythmic drug containing approximately 37 percent iodine by weight, can induce both hypo- and hyperthyroidism, and hyperthyroidism induced by amiodarone can unmask or worsen TED. Women taking amiodarone for arrhythmia should have regular thyroid function tests and TSHR antibody screening if they develop any eye changes.

Lithium

Lithium, used in bipolar disorder, interferes with thyroid hormone synthesis and increases the risk of autoimmune thyroid disease. Women on long-term lithium have a significantly elevated risk of hypothyroidism and Hashimoto's thyroiditis, and cases of lithium-associated TED have been reported, though the evidence base remains limited.

Interferon-Alpha

Interferon-alpha therapy, historically used for hepatitis C and some cancers, is associated with autoimmune thyroiditis and, in Graves'-predisposed individuals, can precipitate TED. Thyroid autoimmunity occurs in 5 to 40 percent of patients on interferon-alpha, with women at higher risk than men.

Checkpoint Inhibitors

Immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4 drugs like pembrolizumab and nivolumab) used in oncology can induce autoimmune thyroiditis and, in rare cases, TED. As these agents are increasingly used for cancers that affect women, including triple-negative breast cancer and cervical cancer, oncology teams and women's health providers need to coordinate thyroid and ocular monitoring.

Drugs That Treat Thyroid Eye Symptoms

Teprotumumab (Tepezza): The FDA-Approved Targeted Therapy

Teprotumumab is the only FDA-approved drug for active TED. It works by blocking the IGF-1R, the key receptor driving orbital fibroblast activation. The key Phase 3 OPTIC trial (Smith et al., NEJM 2020) showed proptosis reduction of 2 mm or more in 83 percent of teprotumumab-treated patients versus 10 percent on placebo after 24 weeks of infusion. The drug is given as eight intravenous infusions over 24 weeks.

Pregnancy and Lactation Safety for Teprotumumab

Teprotumumab is contraindicated during pregnancy. IGF-1R signaling is essential for fetal development, and animal data show embryo-fetal toxicity. The FDA prescribing information requires a negative pregnancy test before each infusion and reliable contraception during treatment and for six months after the last dose. If you are of reproductive age and considering Tepezza, discuss a contraception plan with your provider before starting.

No human lactation data exist for teprotumumab. Given its molecular weight and mechanism, excretion in breast milk cannot be excluded. Breastfeeding is not recommended during treatment or for six months after the last infusion.

Common Side Effects in Women

The most frequently reported side effects in the OPTIC trial were muscle cramps, nausea, alopecia, diarrhea, fatigue, and hyperglycemia. Hearing changes, including sensorineural hearing loss and tinnitus, were identified as a post-marketing concern and are now listed in the prescribing information. Baseline audiometry is recommended before starting treatment. Women with pre-existing diabetes or insulin resistance, including those with PCOS, require blood glucose monitoring during infusions because teprotumumab can worsen glycemic control.

Glucocorticoids (IV Methylprednisolone)

High-dose intravenous methylprednisolone remains a first-line treatment for moderate-to-severe active TED, particularly when teprotumumab is not accessible or not appropriate. European Group on Graves' Orbitopathy (EUGOGO) guidelines recommend IV methylprednisolone 500 mg weekly for 6 weeks, then 250 mg weekly for 6 weeks (total 4.5 g). Cumulative doses above 8 g carry a risk of acute liver injury, so liver function should be monitored.

Women on glucocorticoids should be counseled on bone density loss, particularly those who are postmenopausal or have other osteoporosis risk factors. Calcium, vitamin D, and bisphosphonate co-prescription should be considered for courses lasting more than 6 weeks.

Oral Steroids

Oral prednisone alone is less effective than IV dosing for TED and carries higher systemic risk, including weight gain, blood glucose elevation, mood changes, and adrenal suppression. For women managing hormonal acne, PCOS-related metabolic syndrome, or perimenopausal weight changes, the metabolic effects of prolonged oral steroids deserve explicit discussion.

Selenium Supplementation

A randomized, double-blind, placebo-controlled trial (Marcocci et al., NEJM 2011) showed that selenium 200 mcg daily for 6 months significantly improved mild TED, reducing the Clinical Activity Score and improving quality of life compared with placebo at 12 months. Selenium is an affordable, low-risk adjunct for mild active disease and is recommended by EUGOGO for mild TED. The benefit is seen specifically in selenium-deficient populations, common in parts of Europe, less consistent in selenium-replete regions like the United States.

Rituximab

Rituximab, an anti-CD20 monoclonal antibody, has been studied for TED with mixed results. The CIRTED trial (Salvi et al., NEJM 2015) showed no significant benefit of rituximab over IV methylprednisolone for moderate-to-severe TED. Its use is generally reserved for refractory cases. Women of childbearing age should know that rituximab is teratogenic and requires contraception during treatment and for 12 months after.

Orbital Radiation

Orbital external beam radiotherapy is sometimes used alongside IV steroids for moderate-to-severe active TED, particularly when diplopia is driven by muscle thickening. It is generally avoided in women under 35 due to the proximity of the radiation field to the lens and theoretical cataract risk, and it is contraindicated in diabetic retinopathy.

Surgical Rehabilitation

Once TED enters the inactive (quiescent) phase, surgery addresses structural damage in a specific sequence: orbital decompression first, strabismus surgery second, eyelid surgery last. Decompression is performed when proptosis causes corneal exposure or optic nerve compression. Surgery is not a substitute for medical treatment during the active inflammatory phase.

Life Stage Matters: How TED Behaves Across a Woman's Reproductive Life

Understanding how TED interacts with hormonal life stages gives you and your provider a framework that most generic resources do not address.

Reproductive Years (Ages 18 to 40)

This is the most common window for Graves' disease onset. TED activity typically tracks with overall immune activation, which peaks in the reproductive years. Women with PCOS already carry a higher prevalence of thyroid autoimmunity, with some studies reporting Hashimoto's thyroiditis in up to 26 percent of women with PCOS, making thyroid antibody screening particularly relevant in this group.

Trying to Conceive and Pregnancy

Active Graves' disease and uncontrolled hyperthyroidism are associated with reduced fertility, increased miscarriage risk, and pregnancy complications. TED itself does not directly impair fertility, but the systemic disease does.

Teprotumumab is contraindicated in pregnancy, as noted above. Methimazole, the standard antithyroid drug for Graves', carries teratogenic risk in the first trimester (choanal atresia, aplasia cutis), so many providers switch to propylthiouracil (PTU) for the first trimester, then back to methimazole, following ACOG and ATA guidance. TED symptoms can paradoxically improve during pregnancy due to immune tolerance shifts, then flare postpartum when immune suppression lifts.

Postpartum

The postpartum period carries the highest risk of autoimmune flare. Postpartum thyroiditis affects approximately 5 to 9 percent of women and can unmask or worsen Graves' disease. If you had TED during pregnancy that seemed to settle, postpartum re-emergence is common and should be anticipated. Ophthalmology follow-up in the first six months postpartum is prudent for any woman with a history of TED.

Perimenopause

Graves' disease has a second incidence peak in the perimenopausal decade, roughly the mid-40s to mid-50s. Estrogen decline may alter immune homeostasis, and the overlap of TED symptoms with perimenopausal complaints, including fatigue, mood changes, and sleep disruption, means TED is often delayed in diagnosis at this life stage. Lid puffiness or eye irritation attributed to "aging" or "allergies" in a perimenopausal woman warrants a TRAb check.

Post-Menopause

Post-menopausal women with TED face compounded bone health risk. Glucocorticoid treatment for TED accelerates bone loss on top of already-declining estrogen. Bone density monitoring and consideration of hormone therapy for bone protection should be part of a comprehensive management plan for postmenopausal women needing prolonged steroid courses.

Diagnosing Thyroid Eye Disease

Diagnosis combines clinical assessment, laboratory testing, and imaging.

Clinical Assessment

An ophthalmologist or oculoplastic surgeon measures proptosis with a Hertel exophthalmometer. Proptosis greater than 21 mm or asymmetry greater than 2 mm between eyes is considered abnormal. The Clinical Activity Score (CAS) is a 7-point scale where a score of 3 or more indicates active inflammation amenable to immunosuppressive therapy.

Laboratory Testing

• TSH, free T4, free T3: To establish thyroid status.
• TSHR antibodies (TRAb): Elevated in more than 95 percent of active Graves' disease. Positive TRAb in a euthyroid patient with eye changes confirms euthyroid TED.
• Thyroid peroxidase (TPO) antibodies: Elevated in Hashimoto's-associated TED.

Imaging

Orbital MRI or CT scan visualizes extraocular muscle enlargement, characteristic of TED, particularly the inferior and medial rectus muscles. MRI is preferred for active disease assessment due to the absence of radiation. CT is faster and more practical when optic nerve compression is suspected urgently.

Who This Is Right For and Not Right For

Who Is a Good Candidate for Teprotumumab

• Active TED with a CAS of 3 or higher
• Moderate-to-severe disease with proptosis, diplopia, or quality-of-life impairment
• Women who have failed or cannot tolerate IV glucocorticoids
• Non-pregnant women of any reproductive age using reliable contraception

Who Should Not Use Teprotumumab

• Women who are pregnant or trying to conceive (contraindicated)
• Women breastfeeding (insufficient safety data)
• Patients with pre-existing inflammatory bowel disease (cases of IBD worsening have been reported)
• Women with poorly controlled diabetes: glycemic optimization is needed before and during treatment

When IV Steroids Are Preferred Over Teprotumumab

• Rapid-onset severe disease requiring urgent suppression
• Access or insurance barriers to teprotumumab
• Women who are postmenopausal and managing bone density may need additional protective co-prescribing, but steroids are not contraindicated

When to Pursue Surgery

Surgery is for the inactive phase only. Attempting decompression during active inflammation risks worsening fibrosis. If your CAS has been 0 for at least 6 months and structural damage persists, an oculoplastic surgeon can assess candidacy.

When to Seek Urgent or Emergency Care

See an ophthalmologist the same day for:

• Sudden or worsening double vision
• Decreasing visual acuity or color saturation (colors look washed out)
• Eye pain that wakes you from sleep
• Corneal exposure with inability to fully close your eye

These signs may indicate optic nerve compression or corneal breakdown, both of which can cause permanent vision loss without rapid treatment. Urgent IV steroids or orbital decompression may be required.

The Evidence Gap in Women with TED

Women are the majority of TED patients, yet sex-specific subgroup analyses are largely absent from the major trials. The OPTIC trial enrolled 74 percent women but did not report sex-stratified efficacy or side-effect data. The CIRTED rituximab trial and the selenium trial by Marcocci et al. Similarly lacked sex-disaggregated outcomes. We do not have trial-level data on how hormonal status, menstrual cycle phase, or menopausal stage affects teprotumumab response, steroid metabolism, or selenium efficacy in TED. What is applied to women is largely extrapolated from mixed-sex cohorts. This is worth naming plainly so you can ask your specialist whether the data underlying your treatment recommendation came from people like you.